Cargando…
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075058/ https://www.ncbi.nlm.nih.gov/pubmed/35179040 http://dx.doi.org/10.1161/JAHA.121.020745 |
_version_ | 1784701596453568512 |
---|---|
author | West, Malcolm Kirby, Adrienne Stewart, Ralph A. Blankenberg, Stefan Sullivan, David White, Harvey D. Hunt, David Marschner, Ian Janus, Edward Kritharides, Leonard Watts, Gerald F. Simes, John Tonkin, Andrew M. |
author_facet | West, Malcolm Kirby, Adrienne Stewart, Ralph A. Blankenberg, Stefan Sullivan, David White, Harvey D. Hunt, David Marschner, Ian Janus, Edward Kritharides, Leonard Watts, Gerald F. Simes, John Tonkin, Andrew M. |
author_sort | West, Malcolm |
collection | PubMed |
description | BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long‐Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow‐up, 6 years) and long‐term (median follow‐up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR‐creatinine, then GFR‐creatinine‐cystatin C). Over 6 years, in fully adjusted multivariable time‐to‐event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07–1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19–1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all‐cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR‐creatinine‐cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28–10.20) independently of estimated GFR‐creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR‐creatinine‐cystatin C. CONCLUSIONS: Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all‐cause mortality. Prediction of long‐term mortality was independent of improved estimation of GFR. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12616000535471. |
format | Online Article Text |
id | pubmed-9075058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90750582022-05-10 Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study West, Malcolm Kirby, Adrienne Stewart, Ralph A. Blankenberg, Stefan Sullivan, David White, Harvey D. Hunt, David Marschner, Ian Janus, Edward Kritharides, Leonard Watts, Gerald F. Simes, John Tonkin, Andrew M. J Am Heart Assoc Original Research BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long‐Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow‐up, 6 years) and long‐term (median follow‐up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR‐creatinine, then GFR‐creatinine‐cystatin C). Over 6 years, in fully adjusted multivariable time‐to‐event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07–1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19–1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all‐cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR‐creatinine‐cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28–10.20) independently of estimated GFR‐creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR‐creatinine‐cystatin C. CONCLUSIONS: Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all‐cause mortality. Prediction of long‐term mortality was independent of improved estimation of GFR. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12616000535471. John Wiley and Sons Inc. 2022-02-18 /pmc/articles/PMC9075058/ /pubmed/35179040 http://dx.doi.org/10.1161/JAHA.121.020745 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research West, Malcolm Kirby, Adrienne Stewart, Ralph A. Blankenberg, Stefan Sullivan, David White, Harvey D. Hunt, David Marschner, Ian Janus, Edward Kritharides, Leonard Watts, Gerald F. Simes, John Tonkin, Andrew M. Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study |
title | Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study |
title_full | Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study |
title_fullStr | Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study |
title_full_unstemmed | Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study |
title_short | Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study |
title_sort | circulating cystatin c is an independent risk marker for cardiovascular outcomes, development of renal impairment, and long‐term mortality in patients with stable coronary heart disease: the lipid study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075058/ https://www.ncbi.nlm.nih.gov/pubmed/35179040 http://dx.doi.org/10.1161/JAHA.121.020745 |
work_keys_str_mv | AT westmalcolm circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT kirbyadrienne circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT stewartralpha circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT blankenbergstefan circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT sullivandavid circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT whiteharveyd circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT huntdavid circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT marschnerian circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT janusedward circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT kritharidesleonard circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT wattsgeraldf circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT simesjohn circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT tonkinandrewm circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy AT circulatingcystatincisanindependentriskmarkerforcardiovascularoutcomesdevelopmentofrenalimpairmentandlongtermmortalityinpatientswithstablecoronaryheartdiseasethelipidstudy |